Lessons from two trials of mycophenolate mofetil in myasthenia gravis.
Two randomized controlled trials of mycophenolate mofetil (MMF) in the treatment of myasthenia gravis (MG) were recently completed. Although neither study demonstrated efficacy of MMF in the population of patients studied, there are valuable lessons in the way these studies were developed and performed. After reviewing the design and results of these trials, we discuss possible reasons leading to negative results and the lessons learned, which should be useful for future clinical trials in MG.
Duke University Medical Center, Durham, NC 27710, USA. Donald.Sanders@Duke.edu
Donald B
DB
Sanders
Zaeem A
ZA
Siddiqi
D004359:Drug Therapy, Combination; D006801:Humans; D007167:Immunotherapy; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000276:immunology*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D011239:Prednisolone; D009173:Mycophenolic Acid